An ongoing dialogue on HIV/AIDS, infectious diseases,
November 22nd, 2008
“Salvage” Rx for HIV: Macro Good News, Micro Bad News
I’ve written before how the number of treatment experienced patients who have no options for successful therapy has dwindled to a tiny — but unfortunate — few. Darunavir, maraviroc, raltegravir, and etravirine (in order of FDA approval) are that good.
Two presentations at recent scientific meetings confirmed the staggering efficacy of these newer drugs. Notably, both described response rates that exceeded what was reported in pivotal phase III studies — telling us that if anything, results in clinical practice will be better than in the trials, likely because a broader range of drugs is now available to the prescribing clinician. (By contrast, patients in the MOTIVATE studies of maraviroc couldn’t use darunavir — not yet approved.)
First, this summer at the IAC meeting in Mexico City, a French group described a 90% virologic suppression rate (< 50 at 24 weeks) for 103 patients with triple class resistance receiving raltegravir, etravirine, and darunavir (sometimes with other agents). Second, more recently at ICAAC, a group from Kaiser Permanente reported that 50 out of 53 patients in their etravirine expanded access program were virologically suppressed — many of whom did not even have full susceptibility to darunavir or etravirine.
Wow.
Which brings me to an e-mail I received this week which included the following chilling piece of information:
He has rather resistant virus, and has been on Truvada, Darunavir, Ritonavir, and Raltegravir. His most recent viral loads were 450 then 920 …
Needless to say, my response included a comment that the rising viral load on a raltegravir-based regimen was “worrisome”.
In addition, a patient who is a typical raltegravir success story from our practice — high-level triple class resistance, never previously virologically suppressed, but HIV RNA undetectable for now 2-plus years — had a viral load come back recently at nearly a thousand. (He says he had a cold.) Confirmation of this result is pending (I like to wait at least a couple of weeks before repeating these) so of course this could just be a mega-blip, but needless to say I’m worried about him too.
With the disappointing news on bevirimat presented at ICAAC — showing that some 40% of individuals harbor a polymorphism in the gag region of HIV that makes their viruses essentially resistant to the drug — we don’t really have promising drugs in the pipeline for this group of individuals, however small that group may be.
Let’s hope this precarious state of affairs is a temporary one.
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- The Invisible Load of Cognitive Symptoms July 2, 2026Patients with shrinking cognitive bandwidth may feel their disability keenly in daily life, even if they can pass a controlled test of cognitive capacity. How should clinicians approach and care for them?
- Cat Scratch Disease July 2, 2026A 40-year-old woman presented with a 1-month of history of fevers and 3-week history of swelling in her right armpit. Ultrasonography showed enlarged lymph nodes with an adjacent fluid collection.
- Operative versus Nonoperative Management for Appendicitis July 2, 2026This feature about treatment of appendicitis offers a case vignette accompanied by two essays, one recommending operative management and the other supporting a nonoperative approach.
- Advances in Multiple Sclerosis July 2, 2026This review summarizes advances in the treatment of multiple sclerosis, with emphasis on effective disease-modifying therapies for relapsing disease and the need for better treatments to prevent progression and rebuild myelin.
- Ebola at 50 — Lessons for Outbreak Response and Preparedness July 1, 2026An accurate history of Ebola begins with partnerships, including those between responders and the populations they serve. One of its key lessons is that equity must be integral to outbreak preparedness.
- The Invisible Load of Cognitive Symptoms July 2, 2026